KI 8110

Drug Profile

KI 8110

Latest Information Update: 26 May 2001

Price : $50

At a glance

  • Originator MECT Corporation
  • Developer MECT Corporation; Nonindustrial source
  • Class Antineoplastics; Glycosides; Pyrimidine nucleosides
  • Mechanism of Action CMP-sialic acid transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer metastases

Most Recent Events

  • 26 May 2001 Profile reviewed but no significant changes made
  • 14 Nov 1997 No-Development-Reported for Cancer metastases in USA (Unknown route)
  • 14 Nov 1997 No-Development-Reported for Cancer metastases in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top